Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 null phenotype is a "positive result" in urothelial carcinoma in situ.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Sept 2022

Sangoi Ankur R, Chan Emily, Abdulfatah Eman, Stohr Bradley A, Nguyen Jane, Trpkov Kiril, Siadat Farshid, Hirsch Michelle, Falzarano Sara, Udager Aaron M, Kunju L Priya

Abstract excerpt

The concept of a "p53 null phenotype" (complete loss of staining) is well-recognized in the gynecologic pathology literature, implicitly reflecting that this staining pattern represents a TP53 mutation. However, in the genitourinary pathology literature, a p53 null phenotype has only been addressed regarding the prognosis of invasive urothelial carcinoma, and not as a diagnostic biomarker for urothelial carcinoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma in Situ

Share to Carcinoma, Transitional Cell

Share to Immunohistochemistry

Share to Phenotype

Share to Tumor Suppressor Protein p53

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 35322193
DOI: 10.1038/s41379-022-01062-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 null phenotype is a "positive result" in urothelial carcinoma in situ.PMID 35322193Read ↗

Molecular Pathology of Urothelial Carcinoma.Semantic proximity Read ↗

The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.Semantic proximity Read ↗

Cytoplasmic Pattern p53 Immunoexpression in Pelvic and Endometrial Carcinomas With TP53 Mutation Involving Nuclear Localization Domains: An Uncommon But Potential Diagnostic Pitfall With Clinical Implications.Semantic proximity Read ↗

The Emerging Molecular Landscape of Urothelial Carcinoma.Semantic proximity Read ↗

Inverted urothelial papilloma: Diagnostic challenges, molecular insights, and clinical implications.Semantic proximity Read ↗

Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.Semantic proximity Read ↗

PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates.Semantic proximity Read ↗

Multiprobe Fluorescence in situ Hybridization (UroVysion) for the Detection of Urothelial Carcinoma – FISHing for the Right CatchSemantic proximity Read ↗

A clinical and molecular review of inverted papilloma of the urinary tract: how to handle?Semantic proximity Read ↗

TP53 mutations in urothelial carcinoma: not all one and the same†.Semantic proximity Read ↗

Digital re-classification of equivocal dysplastic urothelial lesions using morphologic and immunohistologic analysisSemantic proximity Read ↗

Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.